Results 61 to 70 of about 28,620 (235)

The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles [PDF]

Drug Metabolism and Disposition, 2015
CYP2C19 rs12769205 alters an intron 2 branch point adenine leading to an alternative mRNA in human liver with complete inclusion of intron 2 (exon 2B). rs12769205 changes the mRNA reading frame, introduces 87 amino acids, and leads to a premature stop codon. The 1000 Genomes project (http://browser.1000genomes.org/index.html) indicated rs12769205 is in
Amarjit S, Chaudhry, Bhagwat, Prasad, Yoshiyuki, Shirasaka, Alison, Fohner, David, Finkelstein, Yiping, Fan, Shuoguo, Wang, Gang, Wu, Eleni, Aklillu, Sarah C, Sim, Kenneth E, Thummel, Erin G, Schuetz   +11 more
openaire   +2 more sources

The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin

Clinical Pharmacology &Therapeutics, EarlyView.
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul, Waseem Mujahed, Ibrahim Idries, Maor Wanounou, Meir Bialer, Yoseph Caraco   +5 more
wiley   +1 more source

Association between CYP2C19 polymorphism and depressive symptoms

, 2010
Cytochrome P450 2C19 (CYP2C19) is a polymorphic enzyme active in the metabolism of for example diazepam and the antidepressants sertraline, citalopram, and escitalopram, whereby allelic variants cause increased (CYP2C19*17) or abolished (mainly CYP2C19*2)
Nordin, L, Sim, S,, Olsson, Marita, Ingelman-Sundberg, M,, Olsson, Marita,, Andersson, T M-L, Pedersen, N,, Virding, S,, Pedersen, N, Ingelman-Sundberg, M, Sim, S, Andersson, T M-L,, Nordin, L,, Virding, S, Andersson, TM-L, Olsson, M, Pedersen, NL, Sim, SC, Marita Olsson, Sarah C. Sim, Susanne Virding, Magnus Ingelman-Sundberg, Therese M.-L. Andersson, Nancy L. Pedersen, Linn Nordin   +24 more
core   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype

, 2015
CYP2C19 is a polymorphic enzyme that metabolizes a wide variety of therapeutic drugs that has been associated with altered enzymatic activity and adverse drug reactions.
MARTINEZ-CORTES, G., SALAZAR-FLORES, J., MARTINEZ-SEVILla, V.M., VELAZQUEZ-SUAREZ, N.Y., RANGEL-VILLALOBOS, H., FAVELA-MENDOZA, A.F., MUNOZ-VALLE, J.F., HERNANDEZ-ZARAGOZA, M.   +7 more
core   +1 more source

Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease

ARYA Atherosclerosis, 2011
BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD).
Arash Akhlaghi, Shahin Shirani, Naghmeh Ziaie, Omid Pirhaji, Majid Yaran, Golnoosh Shahverdi, Nizal Sarrafzadegan, Alireza khosravi, Elham khosravi   +8 more
doaj  

In vitro assessment of the impact of 30 CYP2C19 variants on citalopram metabolism [PDF]

PeerJ
Background CYP2C19 polymorphisms are correlated with individual variability in response to citalopram treatment. The pharmacogenomic testing of CYP2C19 has been shown to optimize the safety and efficacy of citalopram medication. Exploration of the effect
Peng Wang, Xiao-xia Hu, Jun-wei Li
doaj   +2 more sources

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy

Medicine in Drug Discovery, 2020
Objective: Cytochrome CYP2C19 mutant allele is associated with high on-treatment platelet reactivity (HTPR) after standard clopidogrel treatment, which is accompanied by an increased risk of ischemic events. This study assesses the association of CYP2C19
Yawei Yang, Wei Zhang, Pan Li, Ying Gu, Liping Ma, Min Fan   +5 more
doaj   +1 more source

Differences in the Proportion of CYP2C19 Loss-of-Function Between Cerebral Infarction and Coronary Artery Disease Patients

, 2023
Yuliang Shi,1,2 Yuxian Yang,1,2 Miaoling Feng,1,2 Weihan Ling,1,2 Tongguo Wei,1,2 Yumin Cao,1,2 Rui Zhong,1,2 Heming Wu2 1Department of Neurology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China ...
Yang Y, Feng M, Zhong R, Ling W, Wei T, Cao Y, Shi Y, Wu H   +7 more
core